Skip to main content

Table 3 Recent combination checkpoint inhibitor study results in melanoma

From: Novel melanoma therapy

Study Phase of study Prior Tx Agents ORR PFS
[42]
[43]
III No Ipilimumab 19.0 2.9 months
Nivolumab 43.7 6.9 months
Nivolumab + ipilimumab 57.6 11.5 months
[44] III No Nivolumab + ipilimumab 52–61 8.5 months (BRAF mutant)
Not reached (BRAF wildtype)
Ipilimumab 11 2.7 months (BRAF mutant)
4.4 months (BRAF wildtype)
[46] II No Pembrolizumab + ipilimumab 57 70 % at 6 months